鎮静作用(Sedation)の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Sedation Overview 6
Therapeutics Development 7
Pipeline Products for Sedation – Overview 7
Pipeline Products for Sedation – Comparative Analysis 8
Sedation – Therapeutics under Development by Companies 9
Sedation – Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Sedation – Products under Development by Companies 14
Sedation – Companies Involved in Therapeutics Development 15
Advicenne Pharma 15
AstraZeneca PLC 16
Maruishi Pharmaceutical Co., Ltd. 17
NanoMedex Pharmaceuticals, Inc. 18
Paion AG 19
Sedation – Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 28
ABP-700 – Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ADV-6209 – Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
clonidine hydrochloride – Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
MR-04A3 – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
propofol – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
propofol Microemulsion – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
remimazolam – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Sedation – Recent Pipeline Updates 37
Sedation – Dormant Projects 40
Sedation – Discontinued Products 41
Sedation – Product Development Milestones 42
Featured News & Press Releases 42
Oct 14, 2014: Invitation To Conference Call Of Paion About The Project Status Of Remimazolam In Japan 42
Oct 10, 2014: Paion Expects Ono’S Remimazolm Decision On Filing In Japan In November 2014 42
Oct 01, 2014: Two Scientific Remimazolam Presentations Are Accepted for ASA and ACG Meeting in October 2014 43
Aug 11, 2014: Diprivan (Propofol) Injectable Emulsion, USP Now Available in 10 mL Vials 44
Nov 23, 2013: PAION announces positive End-of-Phase II Meeting with FDA for Remimazolam in procedural sedation 45
Aug 05, 2013: GERMAN REGULATORY AUTHORITY APPROVED PHASE II STUDY OF REMIMAZOLAM IN INDICATION ANAESTHESIA 45
Aug 01, 2013: PAION’S PARTNER ONO STOPPED ITS DOSE FINDING, EXPLORATIVE PHASE II TRIAL IN ICU SEDATION WITH REMIMAZOLAM AND PLANS TO ADAPT THE DOSE REGIME FOR A NEW STUDY 45
May 08, 2013: Paion’s Partner Ono Pharma Completes Recruitment For Phase II/III Study Of Remimazolam For General Anesthesia 46
Dec 18, 2012: Paion Receives $3m Milestone Payment From Ono Pharma Following Enrollment Of First Patient In Phase II/III Study Of Remimazolam 46
Nov 05, 2012: Paion’s Partner Ono Pharma Intiates Phase II/III Study With Short-acting Anaesthetic/Sedative Remimazolam In Japan 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49